TherapeuticsMD, Inc. (TXMD)
Total Valuation
TherapeuticsMD has a market cap or net worth of $45.16 million. The enterprise value is $33.71 million.
| Market Cap | 45.16M |
| Enterprise Value | 33.71M |
Important Dates
The last earnings date was Monday, May 15, 2023, after market close.
| Earnings Date | May 15, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 10.26 million shares outstanding. The number of shares has increased by 13.23% in one year.
| Shares Outstanding | 10.26M |
| Shares Change (YoY) | +13.23% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | 6.37% |
| Owned by Institutions (%) | 45.09% |
| Float | 7.67M |
Valuation Ratios
The trailing PE ratio is 0.25 and the forward PE ratio is 2.29. TherapeuticsMD's PEG ratio is -0.73.
| PE Ratio | 0.25 |
| Forward PE | 2.29 |
| PS Ratio | 0.86 |
| Forward PS | 5.64 |
| PB Ratio | 1.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.73 |
Enterprise Valuation
| EV / Earnings | 0.21 |
| EV / Sales | 0.66 |
| EV / EBITDA | 0.24 |
| EV / EBIT | 0.24 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.28 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -8,781.90% and return on invested capital (ROIC) is 7,905.70%.
| Return on Equity (ROE) | -8,781.90% |
| Return on Assets (ROA) | 146.40% |
| Return on Capital (ROIC) | 7,905.70% |
| Revenue Per Employee | $51.05M |
| Profits Per Employee | $157.42M |
| Employee Count | 1 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.25% in the last 52 weeks. The beta is 1.17, so TherapeuticsMD's price volatility has been higher than the market average.
| Beta (1Y) | 1.17 |
| 52-Week Price Change | -58.25% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 5.55 |
| Average Volume (30 Days) | 38,806 |
Short Selling Information
The latest short interest is 312,546, so 3.05% of the outstanding shares have been sold short.
| Short Interest | 312,546 |
| Short Previous Month | 342,345 |
| Short % of Shares Out | 3.05% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 6.13 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $51.05 million and earned $157.42 million in profits. Earnings per share was $17.12.
| Revenue | 51.05M |
| Gross Profit | 54.51M |
| Operating Income | 24.75M |
| Pretax Income | 157.42M |
| Net Income | 157.42M |
| EBITDA | 143.17M |
| EBIT | 143.05M |
| Earnings Per Share (EPS) | $17.12 |
Balance Sheet
The company has $17.25 million in cash and $7.14 million in debt, giving a net cash position of $10.11 million or $0.99 per share.
| Cash & Cash Equivalents | 17.25M |
| Total Debt | 7.14M |
| Net Cash | 10.11M |
| Net Cash Per Share | $0.99 |
| Equity / Book Value | 32.02M |
| Book Value Per Share | 3.12 |
| Working Capital | 5.40M |
Cash Flow
In the last 12 months, operating cash flow was -$7.73 million and capital expenditures $42,000, giving a free cash flow of -$7.69 million.
| Operating Cash Flow | -7.73M |
| Capital Expenditures | 42,000 |
| Free Cash Flow | -7.69M |
| FCF Per Share | -$0.79 |
Margins
Gross margin is 106.78%, with operating and profit margins of 48.49% and 308.38%.
| Gross Margin | 106.78% |
| Operating Margin | 48.49% |
| Pretax Margin | 308.38% |
| Profit Margin | 308.38% |
| EBITDA Margin | 280.48% |
| EBIT Margin | 280.24% |
| FCF Margin | -15.06% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 359.22% |
| FCF Yield | -17.54% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.23% |
| Shareholder Yield | -13.23% |
Analyst Forecast
The average price target for TherapeuticsMD is $7.50, which is 70.46% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.50 |
| Price Target Difference | 70.46% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -35.43% |
| EPS Growth Forecast (5Y) | -58.75% |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |